Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al. Neurology 2020 Jul 20. pii: WNL.0000000000010376.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 2020 Jul 20. pii: WNL.0000000000010376.
PMID: 32690791